WEKO3
アイテム
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
https://asahikawa-med.repo.nii.ac.jp/records/6128
https://asahikawa-med.repo.nii.ac.jp/records/6128dfabe82e-7357-49fc-a2d2-e5c70eeffd42
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学位論文 / Thesis or Dissertation_02(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-10-10 | |||||
タイトル | ||||||
タイトル | Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Biliary tract cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Chemotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Gemcitabine and cisplatin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Prognostic factor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Validation | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||
資源タイプ | doctoral thesis | |||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
その他(別言語等)のタイトル | ||||||
その他のタイトル | 一次化学療法としてゲムシタビン+シスプラチン併用療法を施行した進行胆道癌の予後因子に関する検討 | |||||
著者 |
鈴木, 裕子
× 鈴木, 裕子 |
|||||
著者 ローマ字 | ||||||
値 | Suzuki, Yuko | |||||
書誌情報 |
Journal of gastroenterology 巻 54, 号 3, p. 281-290, 発行日 2019-03-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0944-1174 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s00535-018-1518-3. | |||||
識別番号 その他 | ||||||
内容記述タイプ | Other | |||||
内容記述 | PMID:30298469 | |||||
学位授与番号 | ||||||
学位授与番号 | 乙483 | |||||
学位名 | ||||||
学位名 | 博士(医学) | |||||
学位授与機関 | ||||||
学位授与機関識別子Scheme | kakenhi | |||||
学位授与機関識別子 | 10107 | |||||
学位授与機関名 | 旭川医科大学 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | BACKGROUND: \nFew studies have clearly identified the prognostic factors in patients with advanced biliary tract cancer (BTC) receiving gemcitabine plus cisplatin (GC) which is acknowledged as standard chemotherapy regimen. OBJECTIVES: \nThe aim of this study was to identify predictive factors of the overall survival (OS) in advanced BTC patients receiving GC therapy. METHODS: \nData of 307 patients with advanced BTC who received GC therapy as the first-line chemotherapy at our institution from January 2007 to June 2017 were reviewed retrospectively. The patients were randomly assigned to the investigation or the validation dataset at the ratio of 2:1. Multivariate analysis was conducted to identify the prognostic factors, a prognostic index is proposed from the investigation dataset, and the usefulness of this index was confirmed in the validation dataset. RESULTS: \nMultivariate analysis identified poor performance status, elevated serum lactate dehydrogenase, and elevated neutrophil-to-lymphocyte ratio as independent unfavorable predictors. The patients could be classified into three groups according to these factors, and it was found that the outcomes differed significantly among the three groups (P = 0.0002, good- vs. intermediate-prognosis groups; P = 0.005, intermediate- vs. poor-prognosis groups). When this index was applied to the validation dataset, the OS was confirmed to differ significantly among the three groups (P = 0.04, good- vs. intermediate-prognosis groups, P < 0.0001, intermediate- vs. poor-prognosis groups). CONCLUSIONS: \nWe identified three predictors of the OS in patients with advanced BTC receiving GC therapy in this study, based on which we could classify the patients into three risk groups. |
|||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf |